Interim Results of Hiteck Pharmaceutical's Aponermin Monotherapy for Chondrosarcoma Selected for 2026 ASCO Annual Meeting

See more information

Craftsmanship Alchemy: Taming the "Twin" Impurities in Orforglipron

See more information

Hiteck Biopharmaceutical National Class 1 Innovative Drug Selected as a “61020” Landmark Innovation Achievement of Hubei Province

See more information

Congratulations to Professor Liu Wenbo on publishing significant research findings in《Nature Communications》

See more information